Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Rating of “Buy” by Brokerages

by · The Cerbat Gem

Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA – Get Free Report) have received an average recommendation of “Buy” from the nine research firms that are currently covering the firm, Marketbeat reports. Eight investment analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $22.29.

ZVRA has been the subject of several research reports. Guggenheim upped their target price on Zevra Therapeutics from $20.00 to $22.00 and gave the stock a “buy” rating in a research note on Thursday, March 13th. Wall Street Zen raised Zevra Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, May 22nd. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $25.00 target price on shares of Zevra Therapeutics in a research note on Wednesday, May 14th. Canaccord Genuity Group increased their price objective on Zevra Therapeutics from $23.00 to $25.00 and gave the company a “buy” rating in a research note on Thursday, March 13th. Finally, JMP Securities set a $18.00 price objective on Zevra Therapeutics in a research note on Wednesday, March 12th.

Check Out Our Latest Report on Zevra Therapeutics

Hedge Funds Weigh In On Zevra Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of ZVRA. BNP Paribas Financial Markets bought a new stake in Zevra Therapeutics in the 4th quarter worth about $53,000. GAMMA Investing LLC grew its stake in shares of Zevra Therapeutics by 20,564.1% during the 1st quarter. GAMMA Investing LLC now owns 8,059 shares of the company’s stock valued at $60,000 after acquiring an additional 8,020 shares during the period. Squarepoint Ops LLC grew its stake in shares of Zevra Therapeutics by 36.1% during the 4th quarter. Squarepoint Ops LLC now owns 16,534 shares of the company’s stock valued at $138,000 after acquiring an additional 4,384 shares during the period. Strs Ohio bought a new position in shares of Zevra Therapeutics during the 1st quarter valued at approximately $125,000. Finally, ProShare Advisors LLC bought a new position in Zevra Therapeutics in the 4th quarter worth approximately $145,000. 35.03% of the stock is currently owned by institutional investors.

Zevra Therapeutics Trading Up 1.7%

Shares of ZVRA opened at $9.15 on Friday. The business’s 50-day moving average price is $8.28 and its 200-day moving average price is $8.05. Zevra Therapeutics has a twelve month low of $4.20 and a twelve month high of $9.76. The stock has a market cap of $500.32 million, a PE ratio of -4.82 and a beta of 2.01. The company has a quick ratio of 2.93, a current ratio of 3.02 and a debt-to-equity ratio of 1.46.

Zevra Therapeutics (NASDAQ:ZVRA – Get Free Report) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.15. The company had revenue of $20.40 million for the quarter, compared to analysts’ expectations of $16.96 million. Zevra Therapeutics had a negative net margin of 226.78% and a negative return on equity of 201.05%. During the same period in the prior year, the business earned ($0.40) earnings per share. On average, equities analysts forecast that Zevra Therapeutics will post -1.95 EPS for the current fiscal year.

Zevra Therapeutics Company Profile

(Get Free Report

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.

Recommended Stories